Drug Profile

Bretisilocin - AbbVie/Gilgamesh Pharmaceuticals

Alternative Names: GM-2505

Latest Information Update: 28 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Gilgamesh Pharmaceuticals
Class Antidepressants; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Major depressive disorder
Phase I Depressive disorders

Most Recent Events

17 Oct 2025 AbbVie completes acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
25 Aug 2025 AbbVie and Gilgamesh Pharmaceuticals enters into a definitive agreement to acquire Bretisilocin
27 May 2025 Efficacy and adverse event data from a phase IIa trial in Major depressive disorder released by Gilgamesh Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com